Affiliation:
1. Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL 33136, USA
Abstract
Chemoimmunotherapy and cellular therapy are the mainstay of the treatment of relapsed/refractory (R/R) lymphomas. Development of resistance and commonly encountered toxicities of these treatments limit their role in achieving desired response rates and durable remissions. The Antibody–Drug Conjugate (ADC) is a novel class of targeted therapy that has demonstrated significant efficacy in treating various cancers, including lymphomas. To date, three ADC agents have been approved for different lymphomas, marking a significant advancement in the field. In this article, we aim to review the concept of ADCs and their application in lymphoma treatment, provide an analysis of currently approved agents, and discuss the ongoing advancements of ADC development.
Reference177 articles.
1. Jamil, A., and Mukkamalla, S.K.R. (2023). Lymphoma, StatPearls.
2. Thandra, K.C., Barsouk, A., Saginala, K., Padala, S.A., Barsouk, A., and Rawla, P. (2021). Epidemiology of Non-Hodgkin’s Lymphoma. Med. Sci., 9.
3. Autologous transplantation improves survival rates for follicular lymphoma patients who relapse within two years of chemoimmunotherapy: A multi-center retrospective analysis of consecutively treated patients in the real world;Manna;Leuk. Lymphoma,2019
4. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma;Corradini;Leukemia,2014
5. Treatment resistance in diffuse large B-cell lymphoma;He;Leukemia,2021
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献